Literature DB >> 11013033

Transrenal fixation of aortic stent-grafts for the treatment of infrarenal aortic aneurysmal disease.

P G Bove1, G W Long, G B Zelenock, P J Bendick, M D Khoury, M O Burr, G Bechtel, F Becker, C Huckabone.   

Abstract

PURPOSE: We evaluated our early experience with the transrenal fixation of aortic stent-grafts to determine the efficacy of this procedure and its effects on renal artery patency and hemodynamics.
METHODS: Twenty-eight patients (22 men) had endoluminally placed modular bifurcated stent-grafts with a bare spring structure at the proximal end crossing the origin of both renal arteries; no patient with infrarenal fixation was included for analysis. The mean age of the patients was 75 +/- 7 years (range, 58-86 years); the mean aneurysm size was 5.8 +/- 0.8 cm (range, 4.7-7.2 cm). Eight patients had preoperative or intraoperative angiographic evidence of renal artery atherosclerotic disease, but only four vessels had luminal narrowing of 50% or greater. No complications were noted during stent-graft placement, and all patients have returned for follow-up visits, ranging from 1 to 12 months (mean follow-up, 6 +/- 4 months). Follow-up evaluations included clinical assessment, duplex ultrasound scan of the renal arteries and kidneys, and computed tomographic angiography.
RESULTS: No evidence of lobular or sublobular perfusion defects of the renal parenchyma was detected postoperatively. Two patients exhibited postoperative changes in renal artery hemodynamics-one progressing from a 30% diameter reduction to a greater than 60% diameter stenosis at the 12-month follow-up visit and one with a normal renal artery preoperatively having elevated flow velocities indicative of a greater than 60% stenosis at the 1-month visit. Of 19 patients with normal preoperative renal function, only one has had persistently elevated serum creatinine levels.
CONCLUSION: We conclude from this experience that the transrenal placement of open stents is safe and effectively excludes the aneurysm, potentially expanding the availability of this technique to more patients with a short infrarenal aortic neck. Long-term follow-up is essential to determine the overall efficacy of this technique and to identify potential effects on renal artery hemodynamics or kidney function.

Entities:  

Mesh:

Year:  2000        PMID: 11013033     DOI: 10.1067/mva.2000.110051

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

1.  Suprarenal fixation of endograft in abdominal aortic aneurysm treatment: focus on renal function.

Authors:  Franco Grego; Paolo Frigatti; Michele Antonello; Sandro Lepidi; Roberto Ragazzi; Vincenzo Iurilli; Pietro Zucchetta; Giovanni P Deriu
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

2.  Helical CT angiography of fenestrated stent grafting of abdominal aortic aneurysms.

Authors:  Z Sun
Journal:  Biomed Imaging Interv J       Date:  2009-04-01

3.  Endovascular stent graft repair of abdominal aortic aneurysms: Current status and future directions.

Authors:  Zhonghua Sun
Journal:  World J Radiol       Date:  2009-12-31

Review 4.  Branched endovascular stent-graft for suprarenal aortic aneurysm: the future of aortic stent-grafting?

Authors:  Leonard W Tse; Oren K Steinmetz; Cherrie Z Abraham; David A Valenti; Kent S Mackenzie; Daniel I Obrand; Timothy A Chuter
Journal:  Can J Surg       Date:  2004-08       Impact factor: 2.089

5.  Multislice CT angiography of fenestrated endovascular stent grafting for treating abdominal aortic aneurysms: a pictorial review of the 2D/3D visualizations.

Authors:  Zhonghua Sun; Bibombe P Mwipatayi; Yvonne B Allen; David E Hartley; Michael M Lawrence-Brown
Journal:  Korean J Radiol       Date:  2009-04-22       Impact factor: 3.500

6.  Fenestrated stent graft repair of abdominal aortic aneurysm: hemodynamic analysis of the effect of fenestrated stents on the renal arteries.

Authors:  Zhonghua Sun; Thanapong Chaichana
Journal:  Korean J Radiol       Date:  2009-12-28       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.